Superworth

Amneal Pharmaceuticals EV/EBIT AMRX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2018.

Today, Oct 23, 2026
18.3×
8-year median
18.1×
Against its 8-year history
51st
percentile: 0 is its lowest day, 100 its highest
8-year range
12.1× to 117×
Peer median
57.7×

Amneal Pharmaceuticals' EV/EBIT is 18.3× as of Oct 23, 2026.

That is above its 8-year median of 18.1×, close to the middle of its last 8 years.

Over that time it ranged from 12.1× in May 2025 to 117× in Sep 2019.

The median for 10 large drugmakers of a similar size is 57.7×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far18.3×13.4×18.6×
202517.1×12.1×17.1×
202415.7×15.6×19.3×
202317.1×14.8×23.5×
202222.5×19.8×25.2×
202121.1×19.8×52.1×
202047.9×46.1×47.9×
2019116×80.5×117×
201887.4×84.7×109×

Against its peers

Companies in Drug Manufacturers - General nearest Amneal Pharmaceuticals' size, closest first, today.

CompanyEV/EBIT
AMRXAmneal Pharmaceuticals18.3×
LGNDLigand Pharmaceuticals57.7×
KNSAKiniksa Pharmaceuticals International54.6×
ALKSAlkermes plc.69.6×
TGTXTG Therapeutics62.2×
PTGXProtagonist Therapeutics140×
CORTCorcept Therapeuticsn/m
INDVIndivior Pharmaceuticals7.8×
ARQTArcutis Biotherapeutics111×
BMRNBiomarin Pharmaceutical25.8×
LQDALiquidia21.7×
Peer median57.7×

Where Amneal Pharmaceuticals ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Amneal Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.